In the per-protocol population, stroke or systemic embolism occurred in 188 patients who received rivaroxaban and 241 patients who received warfarin (1.7 vs 2.2%; hazard ratio [HR]: 0.79; ...
22,23 The ROCKET AF trial demonstrated that when rivaroxaban was used in AF patients at moderate to high risk for stroke, the drug was found to be noninferior to warfarin for the prevention of ...
Adapted with permission from [9,21]. Events Rivaroxaban (number per 100 patient years) Warfarin (number per 100 patient years) Rivaroxaban versus warfarin hazard ratio (95% CI) Primary safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback